Personalized peptide vaccination in patients with refractory non-small cell lung cancer

  • Authors:
    • Koichi Yoshiyama
    • Yasuhiro Terazaki
    • Satoko Matsueda
    • Shigeki Shichijo
    • Masanori Noguchi
    • Akira Yamada
    • Takashi Mine
    • Tetsuya Ioji
    • Kyogo Itoh
    • Kazuo Shirouzu
    • Tetsuro Sasada
    • Shinzo Takamori
  • View Affiliations

  • Published online on: February 1, 2012     https://doi.org/10.3892/ijo.2012.1351
  • Pages: 1492-1500
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Since the prognosis of non-small cell lung cancer (NSCLC) remains poor, the development of novel therapeutic approaches, including cancer vaccines, is highly desirable. In the current study, we conducted a phase II study of personalized peptide vaccination (PPV), in which a maximum of 4 peptides were selected based on pre-existing humoral immune responses and administered subcutaneously (weekly for 6 consecutive weeks and bi-weekly thereafter) in refractory NSCLC patients. Forty-one refractory NSCLC patients (4 stage IIIb, 22 stage IV and 15 recurrent), who had failed to respond to chemotherapy and/or targeted therapy (median number of regimens, 3; median duration, 10 months), were enrolled. Median overall survival (OS) was 304 days with a one-year survival rate of 42% in the enrolled patients. The main toxicity of PPV was skin reactions at the injection sites, but no serious adverse events were observed. In order to identify potential biomarkers for predicting OS, pre-vaccination and post-vaccination clinical findings and laboratory data were retrospectively assessed and evaluated by multivariate Cox regression analysis. Among the pre-vaccination factors examined, high C-reactive protein (CRP) level was a significant predictor of unfavorable OS [hazard ratio (HR)=10.115, 95% confidence interval (CI)=2.447-41.806, P=0.001]. Among the post-vaccination factors, high CRP level and low frequency of CD3+CD26+ cells were significant predictors of unfavorable OS (HR=23.127, 95% CI=2.919-183.233, P=0.003; HR=0.952, 95% CI=0.917-0.989, P=0.012). Taken together, our results suggest the feasibility of PPV for the treatment of refractory NSCLC. Evaluation of the identified factors before or at an early stage of vaccination could be potentially useful for selecting NSCLC patients who would likely have better prognosis following PPV.

Related Articles

Journal Cover

May 2012
Volume 40 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Shirouzu K, et al: Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 40: 1492-1500, 2012
APA
Yoshiyama, K., Terazaki, Y., Matsueda, S., Shichijo, S., Noguchi, M., Yamada, A. ... Takamori, S. (2012). Personalized peptide vaccination in patients with refractory non-small cell lung cancer. International Journal of Oncology, 40, 1492-1500. https://doi.org/10.3892/ijo.2012.1351
MLA
Yoshiyama, K., Terazaki, Y., Matsueda, S., Shichijo, S., Noguchi, M., Yamada, A., Mine, T., Ioji, T., Itoh, K., Shirouzu, K., Sasada, T., Takamori, S."Personalized peptide vaccination in patients with refractory non-small cell lung cancer". International Journal of Oncology 40.5 (2012): 1492-1500.
Chicago
Yoshiyama, K., Terazaki, Y., Matsueda, S., Shichijo, S., Noguchi, M., Yamada, A., Mine, T., Ioji, T., Itoh, K., Shirouzu, K., Sasada, T., Takamori, S."Personalized peptide vaccination in patients with refractory non-small cell lung cancer". International Journal of Oncology 40, no. 5 (2012): 1492-1500. https://doi.org/10.3892/ijo.2012.1351